Metabolon Inc, a global biochemical profiling and diagnostics company, and the Cystic Fibrosis Foundation are teaming up for future research of cystic fibrosis (CF). A series of studies will be conducted to examine the chemical reactions that occur at the cellular level of CF. The studies are intended to help understand more about CF and its effects on the human body.
"Metabolon’s tools for analyzing complex biological samples will allow us to better understand the basic mechanisms of cystic fibrosis and identify potential biomarkers for disease progression,” says Diana Wetmore, vice president of alliance management for the Cystic Fibrosis Foundation.
“We are excited to help the Foundation bridge the gap between laboratory findings and the advancement of potential new treatments for this disease,” says John Ryals, chief executive of Metabolon. “Through our studies with the Foundation, we will be able to offer additional insight into biochemical processes and biomarkers to help enhance the Foundation’s extensive repository of knowledge about cystic fibrosis.”
